Dr. Clay Siegall, president, co-founder and CEO of Seattle Genetics, is one of the top cancer-research specialists in the world. He is a firm believer of hard work, perseverance and dedication. Seattle Genetics displays a direct reflection of Dr. Siegall’s principles as this biotech company has climbed the ranks of cancer-research success. Dr. Siegall already has this phenomenal company on top of its game, but he is trying to take it even further in the future. This amazing doctor/scientist holds at least 15 patents, and he has just launched an office overseas to expand the company’s growth.
Thanks to owning many of the company’s patents, Seattle Genetics will be able to retain much of its monetary kickbacks. In the company’s earlier days, Seattle Genetics and Dr. Clay Siegall didn’t have this luxury as most of its generated incomes was being funneled to other patent holders such as Takeda Oncology. Learning from your mistakes is a great route to take and as of now, Dr. Siegall is controlling his company’s destiny by retaining many of the company’s rights. Seattle Genetics has a wide selection of drugs in its pipeline as of now. These drugs will be entering the market in future years. The company’s premier drug, ADCETRIS, is still bringing in hundreds of millions of dollars, and it is still being used all around the globe. Seattle Genetics may appear to be bland and boring from its outside appearance, but it is kicking butt when it comes to fighting cancer.
The company’s trajectory has skyrocketed over the past few years. In 2016, Seattle Genetics brought-in $418 million. “We didn’t start making huge profits until about 10 years after securing our IPO,” said Dr. Siegall. So, what is the future for Dr. Siegall and Seattle Genetics? After reading this article, is there any doubt that this company will continue its success?